+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Rare Disease Genetic Testing Market Research Report by Disease Type (Cancer, Cardiovascular Disorders, and Dermatology Diseases), Technology, Specialty, End-user, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 137 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5533236
UP TO OFF until Dec 31st 2022
The United States Rare Disease Genetic Testing Market size was estimated at USD 214.68 million in 2021, USD 241.65 million in 2022, and is projected to grow at a CAGR 14.63% to reach USD 487.15 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Rare Disease Genetic Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Disease Type, the market was studied across Cancer, Cardiovascular Disorders, Dermatology Diseases, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
  • Based on Technology, the market was studied across Array Technology, FISH, Karyotyping, Next Generation Sequencing, PCR - based Testing, and Sanger Sequencing. The Next Generation Sequencing is further studied across Whole Exome Sequencing and Whole Genome Sequencing.
  • Based on Specialty, the market was studied across Biochemical Genetic Tests, Chromosomal Genetic Tests, and Molecular Genetic Tests.
  • Based on End-user, the market was studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Rare Disease Genetic Testing market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Rare Disease Genetic Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Rare Disease Genetic Testing Market, including 23&Me Inc., 3billion, Inc., Associated Regional and University Pathologists, Inc., Baylor Miraca Genetics Laboratories, LLC, Centogene N.V., Color Genomics, Inc., Coopersurgical, Inc., Eurofins Scientific SE, Fulgent Genetics, Inc, Health Network Laboratories, L.P., Invitae Corporation, Laboratory Corporation of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., OPKO Health, Inc., PerkinElmer Inc., PreventionGenetics LLC, Progenity, Inc., Quest Diagnostics Incorporated, Sanofi S.A., and Strand Life Sciences Pvt. Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Rare Disease Genetic Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Rare Disease Genetic Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Rare Disease Genetic Testing Market?
4. What is the competitive strategic window for opportunities in the United States Rare Disease Genetic Testing Market?
5. What are the technology trends and regulatory frameworks in the United States Rare Disease Genetic Testing Market?
6. What is the market share of the leading vendors in the United States Rare Disease Genetic Testing Market?
7. What modes and strategic moves are considered suitable for entering the United States Rare Disease Genetic Testing Market?
Frequently Asked Questions about the U.S. Rare Disease Genetic Testing Market

What is the estimated value of the U.S. Rare Disease Genetic Testing Market?

The U.S. Rare Disease Genetic Testing Market was estimated to be valued at $214.68 Million in 2021.

What is the growth rate of the U.S. Rare Disease Genetic Testing Market?

The growth rate of the U.S. Rare Disease Genetic Testing Market is 14.6%, with an estimated value of $487.15 Million by 2027.

What is the forecasted size of the U.S. Rare Disease Genetic Testing Market?

The U.S. Rare Disease Genetic Testing Market is estimated to be worth $487.15 Million by 2027.

Who are the key companies in the U.S. Rare Disease Genetic Testing Market?

Key companies in the U.S. Rare Disease Genetic Testing Market include 23&Me Inc., 3billion, Inc., Associated Regional and University Pathologists, Inc., Baylor Miraca Genetics Laboratories, LLC, Centogene N.V., Color Genomics, Inc., Coopersurgical, Inc., Eurofins Scientific SE and Health Network Laboratories, L.P..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Rare Disease Genetic Testing Market, by Disease Type
6.1. Introduction
6.2. Cancer
6.3. Cardiovascular Disorders
6.4. Dermatology Diseases
6.5. Endocrine & Metabolism Diseases
6.6. Hematology Diseases
6.7. Immunological Disorders
6.8. Musculoskeletal Disorders
6.9. Neurological Disorders
7. Rare Disease Genetic Testing Market, by Technology
7.1. Introduction
7.2. Array Technology
7.3. Fish
7.4. Karyotyping
7.5. Next Generation Sequencing
7.5.1. Whole Exome Sequencing
7.5.2. Whole Genome Sequencing
7.6. Pcr - Based Testing
7.7. Sanger Sequencing
8. Rare Disease Genetic Testing Market, by Specialty
8.1. Introduction
8.2. Biochemical Genetic Tests
8.3. Chromosomal Genetic Tests
8.4. Molecular Genetic Tests
9. Rare Disease Genetic Testing Market, by End-User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Laboratories & Cros
10. California Rare Disease Genetic Testing Market11. Florida Rare Disease Genetic Testing Market12. Illinois Rare Disease Genetic Testing Market13. New York Rare Disease Genetic Testing Market14. Ohio Rare Disease Genetic Testing Market15. Pennsylvania Rare Disease Genetic Testing Market16. Texas Rare Disease Genetic Testing Market
17. Competitive Landscape
17.1. Fpnv Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, by Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion
18. Company Usability Profiles
18.1. 23&Me Inc.
18.2. 3Billion, Inc.
18.3. Associated Regional and University Pathologists, Inc.
18.4. Baylor Miraca Genetics Laboratories, LLC
18.5. Centogene N.V.
18.6. Color Genomics, Inc.
18.7. Coopersurgical, Inc.
18.8. Eurofins Scientific Se
18.9. Fulgent Genetics, Inc
18.10. Health Network Laboratories, L.P.
18.11. Invitae Corporation
18.12. Laboratory Corporation of America Holdings
18.13. Macrogen, Inc.
18.14. Myriad Genetics, Inc.
18.15. Opko Health, Inc.
18.16. Perkinelmer Inc.
18.17. Preventiongenetics LLC
18.18. Progenity, Inc.
18.19. Quest Diagnostics Incorporated
18.20. Sanofi S.A.
18.21. Strand Life Sciences Pvt. Ltd.
19. Appendix
19.1. Discussion Guide
19.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES RARE DISEASE GENETIC TESTING MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES RARE DISEASE GENETIC TESTING MARKET DYNAMICS
FIGURE 8. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2027
FIGURE 11. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, 2019-2027 (USD MILLION)
FIGURE 20. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, 2019-2027 (USD MILLION)
FIGURE 22. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2019-2027 (USD MILLION)
FIGURE 24. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2019-2027 (USD MILLION)
FIGURE 26. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (%)
FIGURE 28. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2027
FIGURE 30. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, 2019-2027 (USD MILLION)
FIGURE 33. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, 2019-2027 (USD MILLION)
FIGURE 35. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 36. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2019-2027 (USD MILLION)
FIGURE 37. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 38. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, 2019-2027 (USD MILLION)
FIGURE 39. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 40. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, 2019-2027 (USD MILLION)
FIGURE 41. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 42. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, 2019-2027 (USD MILLION)
FIGURE 43. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 44. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, 2019-2027 (USD MILLION)
FIGURE 45. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 46. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2021 VS 2027 (%)
FIGURE 47. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2021 VS 2027 (USD MILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2027
FIGURE 49. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, 2019-2027 (USD MILLION)
FIGURE 50. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 51. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, 2019-2027 (USD MILLION)
FIGURE 52. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 53. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, 2019-2027 (USD MILLION)
FIGURE 54. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 55. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 56. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2027
FIGURE 58. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2019-2027 (USD MILLION)
FIGURE 59. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 60. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2019-2027 (USD MILLION)
FIGURE 61. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 62. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, 2019-2027 (USD MILLION)
FIGURE 63. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 64. CALIFORNIA RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. FLORIDA RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. ILLINOIS RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. NEW YORK RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. OHIO RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 69. PENNSYLVANIA RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. TEXAS RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. UNITED STATES RARE DISEASE GENETIC TESTING MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 72. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 73. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES RARE DISEASE GENETIC TESTING MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY STATE, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY STATE, 2019-2027 (USD MILLION)
TABLE 23. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 24. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 25. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 26. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 27. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 28. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY STATE, 2019-2027 (USD MILLION)
TABLE 31. CALIFORNIA RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 32. CALIFORNIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 33. CALIFORNIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 34. CALIFORNIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 35. CALIFORNIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 36. FLORIDA RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 37. FLORIDA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 38. FLORIDA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 39. FLORIDA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 40. FLORIDA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 41. ILLINOIS RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 42. ILLINOIS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 43. ILLINOIS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 44. ILLINOIS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 45. ILLINOIS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 46. NEW YORK RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 47. NEW YORK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 48. NEW YORK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 49. NEW YORK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 50. NEW YORK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 51. OHIO RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 52. OHIO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 53. OHIO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 54. OHIO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 55. OHIO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 56. PENNSYLVANIA RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. PENNSYLVANIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 58. PENNSYLVANIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 59. PENNSYLVANIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 60. PENNSYLVANIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 61. TEXAS RARE DISEASE GENETIC TESTING MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. TEXAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 63. TEXAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2019-2027 (USD MILLION)
TABLE 64. TEXAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2019-2027 (USD MILLION)
TABLE 65. TEXAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 66. UNITED STATES RARE DISEASE GENETIC TESTING MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 67. UNITED STATES RARE DISEASE GENETIC TESTING MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 68. UNITED STATES RARE DISEASE GENETIC TESTING MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 69. UNITED STATES RARE DISEASE GENETIC TESTING MARKET RANKING
TABLE 70. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2021
TABLE 71. UNITED STATES RARE DISEASE GENETIC TESTING MARKET MERGER & ACQUISITION
TABLE 72. UNITED STATES RARE DISEASE GENETIC TESTING MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 73. UNITED STATES RARE DISEASE GENETIC TESTING MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 74. UNITED STATES RARE DISEASE GENETIC TESTING MARKET INVESTMENT & FUNDING
TABLE 75. UNITED STATES RARE DISEASE GENETIC TESTING MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 76. UNITED STATES RARE DISEASE GENETIC TESTING MARKET: LICENSE & PRICING

Companies Mentioned

  • 23&Me Inc.
  • 3billion, Inc.
  • Associated Regional and University Pathologists, Inc.
  • Baylor Miraca Genetics Laboratories, LLC
  • Centogene N.V.
  • Color Genomics, Inc.
  • Coopersurgical, Inc.
  • Eurofins Scientific SE
  • Fulgent Genetics, Inc
  • Health Network Laboratories, L.P.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Macrogen, Inc.
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • PreventionGenetics LLC
  • Progenity, Inc.
  • Quest Diagnostics Incorporated
  • Sanofi S.A.
  • Strand Life Sciences Pvt. Ltd.

Methodology

Loading
LOADING...